Cardiology Research Institute, Tomsk National Research Medical Center

QR Code

Cardiology Research Institute, Tomsk National Research Medical Center

Aim. To assess the prognostic role of cardiac biomarkers (galectin-3, soluble ST2 (sST2), and N-terminal pro-brain natriuretic peptide (NT-proBNP)) in risk stratification of adverse cardiovascular events (CVEs) in patients with heart failure (HF) after implantation of an automatic implantable cardio...

Full description

Saved in:

Bibliographic Details
Main Authors:	E. V. Grakova, K. V. Kopyeva, A. T. Teplyakov, L. K. Isakov, M. N. Sinkova, N. I. Tarasov
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2022-08-01
Series:	Российский кардиологический журнал
Subjects:	heart failure adverse cardiovascular events implantable cardioverterdefibrillator biomarkers galectin-3 prognosis
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/4753
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Prognosis of cardiovascular events after implantation of a cardioverterdefibrillator in patients with chronic heart failure: the value of increasing concentration of endothelin-1 and soluble forms of ST2 protein in blood plasma
by: A. T. Teplyakov, et al.
Published: (2018-09-01)

Cardiology Research Institute, Tomsk National Research Medical Center
by: B. A. Tatarsky, et al.
Published: (2020-08-01)

Galectins, antibodies to them and galectin-3 binding protein in systemic lupus erythematosus
by: L. V. Kondratyeva, et al.
Published: (2025-03-01)

EFFICACY OF CARDIOVERTER-DEFIBRILLATORS IN PREVENTION OF SUDDEN DEATH AND OVERALL MORTALITY DECREASE IN PATIENTS WITH THE SYNDROME OF DILATION CARDIOMYOPATHY: DIFFERENTIAL APPROACH
by: O. V. Blagova, et al.
Published: (2018-03-01)

Prediction role of a novel biomarker ST2 in risk assessment of adverse cardiovascular events in chronic heart failure with preserved and intermediate ejection fraction after myocardial revascularization
by: E. V. Grakova, et al.
Published: (2018-10-01)

The Role of Cystatin C and Galectin-3 in Cardiorenal Syndrome
by: Nazar Ahemd Naji, et al.
Published: (2023-02-01)

Galectin-3 in the blood serum of patients with bone tumors
by: N. E. Kushlinskii, et al.
Published: (2023-07-01)

Clinical use of the new biomarker ST2 in patients with chronic heart failure of ischemic genesis: an exercise test
by: E. V. Grakova, et al.
Published: (2019-09-01)

Galectin-3 in heart transplant rejection and fibrosis
by: O. P. Shevchenko, et al.
Published: (2019-10-01)

Predictors of Major Adverse Cardiovascular Events in Stable Patients After ST Elevation Myocardial Infarction
by: Lidija Savic, et al.
Published: (2025-05-01)

An Exploratory Research to Evaluate the 30 Most Common Pulmonary Embolism Drugs in the Food and Drug Administration Adverse Event Reporting System
by: Hang Chen, et al.
Published: (2025-06-01)

Biomarkers in predicting mortality from cardiovascular events in patients with heart failure and an implanted cardioverter-defibrillator
by: N. N. Ilov, et al.
Published: (2023-10-01)

Galectins: a potential pharmacological target
by: V. A. Serebryakova, et al.
Published: (2024-10-01)

Sedation-related Adverse Events Associated with a Diagnostic Upper Endoscopy: A Single Center-observational Study
by: Jihyun Lee, et al.
Published: (2017-12-01)

Interactions between galectin-3 and cardiovascular risk in patients with chronic lymphocytic leukemia in remission: results of 3-year prospective study
by: B. B. Samura
Published: (2018-10-01)

Reducing fluoroscopy time during cardioverter-defibrillator implantation, performed with considering of myocardium perfusion scintigraphy results in patients with coronary artery disease
by: T. A. Atabekov, et al.
Published: (2018-12-01)

ECG Abnormalities and Biomarkers Enable Rapid Risk Stratification in Normotensive Patients With Acute Pulmonary Embolism
by: Siqi Jiao, et al.
Published: (2025-06-01)

The prognostic value of the NT-proBNP biomarkers and Fas ligand in assessing the risk of cardiotoxicity of anthracycline chemotherapy
by: A. T. Teplyakov, et al.
Published: (2019-03-01)

Circulative biomarkers as predictors of cardiovascular events in patients after treatment of Hodgkin lymphoma
by: B. B. Samura
Published: (2017-12-01)

Prognosis of Adverse Outcomes in the Research of Coronary Blood Flow During Echocardiography
by: E. S. Kalinina, et al.
Published: (2023-05-01)

Adverse events associated with Implantable Collamer Lens: insights from the FDA MAUDE database
by: Qing Chen, et al.
Published: (2025-07-01)

Galectin-1 and Galectin-3 expression in colon cancer and its correlation with tumor invasion, differentiation, and metastatic spread
by: Yu. V. Kolobovnikova, et al.
Published: (2021-12-01)

Cancer Research Institute, Tomsk National Research Medical Center of the RAS
by: E. L. Choynzonov, et al.
Published: (2019-07-01)

Descriptive Analysis of Reported Adverse Events Associated with Vitiligo Medications Using FDA Adverse Event Reporting System (FAERS) Databases 2013–2023
by: Saleh F. Alqifari, et al.
Published: (2025-07-01)

Importance of blood biomarker determination in the selection of patients with heart failure for cardioverterdefibrillator implantation
by: N. N. Ilov, et al.
Published: (2023-11-01)

Risk factors and long-term prognostic impact of immune related pancreatic injury in patients receiving immune checkpoint inhibitors
by: Yu Akazawa, et al.
Published: (2025-07-01)

Growth Differentiation Factor 15 Predicts Cardiovascular Events in Peripheral Artery Disease
by: Ben Li, et al.
Published: (2025-07-01)

The Role of Integrated Nursing Interventions in Traumatic Brain Injury Management in the Emergency Department: A Retrospective Study
by: Zhou Y, et al.
Published: (2025-05-01)

DARE-SAFE: Denominator-Adjusted Rate Estimates of Substance Adverse Events Frequency Evaluation in Pharmaceuticals and Vaccines
by: Matthew Halma, et al.
Published: (2025-03-01)

Effect of a garlic drench on Galectin gene expression in ovine whole blood
by: SreeNavya Inupala, et al.
Published: (2024-12-01)

Avaliação da ruptura assintomática de implantes mamários preenchidos com gel de silicone Silimed
by: Wanda Elizabeth Massiere-y-Corrêa
Published: (2025-01-01)

Serious skin reaction induced by leflunomide in a patient with juvenilechronic arthritis
by: Y V Muravjov, et al.
Published: (2009-02-01)

ADVERSE EVENT OF DRUG THERAPY (THE FIRST RESULTS OF THE STUDY ACCORDING TO THE PROFILE OUTPATIENT REGISTER)
by: Yu. V. Lukina, et al.
Published: (2016-06-01)

Safety of COVID-19 vaccines
by: B. K. Romanov
Published: (2022-12-01)

Clinical and prognostic significance of biomarker ratios in patients with heart failure and concomitant atrial fibrillation and diabetes mellitus
by: N.M. Kulaiets, et al.
Published: (2025-04-01)

Efficacy and safety of narlumosbart, an anti-RANKL monoclonal antibody, in postmenopausal women with osteoporosis: a multi-center, randomized, double-blind, placebo- and active-controlled, phased II studyResearch in context
by: Yue Chi, et al.
Published: (2025-07-01)

Association between the atherogenic index of plasma and major adverse cardiovascular events in patients with premature coronary artery disease
by: Xiangzhen Ran, et al.
Published: (2025-06-01)

Safety and tolerability of rituximab in the treatment of systemic sclerosis
by: L. A. Garzanova, et al.
Published: (2023-04-01)

Study of association of concomitant diseases with chemotherapy tolerability in children with active tuberculosis: results of a retrospective cohort research
by: M. A. Romanova, et al.
Published: (2016-06-01)

Conventional (D-dimer) and potential (pentraxin 3 and sST2) biomarkers in long-term prognosis of adverse cardiovascular events in COVID-19 survivors without significant cardiovascular diseases
by: T. V. Kanaeva, et al.
Published: (2025-05-01)